BOSTON, Nov. 10, 2015 /PRNewswire/ -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), a women's health specialty pharmaceutical company, today announced the slate of speakers expected to present at its Investor Day on November 11 at the Union League Club in NYC.
Juniper's executive management team will be joined by members of its Scientific Advisory Board who will provide insights into its pipeline and key development programs. Scientific presentations will be given by:
- Ginger Constantine, MD Former Head of Women's Health & Bone Repair Medical Research, Wyeth Research
- William Crowley, MD Daniel K. Podolsky Professor of Medicine, Harvard Medical School; Director, Harvard Reproductive Endocrine Science Center; Director of Clinical Research, Mass. General Hospital; IVR co-founder
- Robert Langer, PhD1 David H. Koch Institute Professor, Massachusetts Institute of Technology (MIT); IVR co-founder
- Bridget Martell, MD, MA Chief Medical Officer, Juniper Pharmaceuticals
- Daniel Shames, MD, FACS Former Director, Division of Reproductive & Urologic Drug Products, FDA
"We are honored to have these distinguished researchers and practitioners share their insights with our guests at Juniper's Investor Day," stated Frank Condella, Juniper's Chief Executive Officer. "We look forward to updating investors on COL-1077 10% lidocaine bioadhesive vaginal gel, and unveiling our new development programs utilizing our novel, segmented intravaginal ring technology, with robust discussion of the underserved medical needs in women's health that we aim to address with our pipeline."
As previously announced, the Company's Investor Day will be broadly accessible via webcast through http://ir.juniperpharma.com or click here. The live webcast will begin at 10:00 a.m. EST on Wednesday, November 11, 2015.
A replay of the Investor Day webcast will be available approximately two hours following completion of the event at the aforementioned URLs. The archived webcast will be available for 90 days.
In-person attendance at the Juniper Investor Day is by invitation only, and an RSVP is required.
About Juniper Pharmaceuticals
Juniper Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing therapeutics that address unmet medical needs in women's health. Juniper has a commercial product, CRINONE® 8% (progesterone gel), which is marketed by Allergan, Inc. in the U.S. and by Merck KGaA, Darmstadt, Germany, in over 90 countries worldwide. The Company is advancing a pipeline of proprietary drug candidates leveraging novel delivery technologies. Please visit www.juniperpharma.com for more information.
Juniper Pharmaceuticals™ and Juniper Pharma Services™ are trademarks of Juniper Pharmaceuticals, Inc., in the U.S. and EU.
CRINONE® is a registered trademark of Allergan, Inc. in the U.S. and of Merck KGaA, Darmstadt, Germany, outside the U.S.
Forward Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This communication contains forward-looking statements, which statements are usually indicated by the words "may," "will," "plans," "believes," "expects," "anticipates," "potential," "should," or similar expressions, and which are generally not historical in nature. These include all statements relating to expected presentations at the Investor Day and the content thereof. Management believes that these forward-looking statements are reasonable as and when made. However, such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. These statements are based on management's current expectations and Juniper Pharmaceuticals does not undertake any responsibility to revise or update any forward-looking statements contained herein, except as expressly required by law. For a discussion of certain risks and uncertainties associated with Juniper Pharmaceuticals' forward-looking statements, please review the Company's reports filed with the SEC, including, but not limited to, its Annual Report on Form 10-K for the period ended December 31, 2014.
Contact: Amy Raskopf Director, Corporate Communications Juniper Pharmaceuticals (917) 673-5775 email@example.com
Follow us on LinkedIn
SOURCE Juniper Pharmaceuticals, Inc.